Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Believe it or not, there's something worse than male pattern baldness. It's depression, plunging libido and shrinking genitals. Those are the symptoms doct ...

Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Hims Topical Finasteride & Minoxidil Spray is ... this specific product isn’t FDA-approved. Thinning hair and hair loss can occur for a variety of reasons. Determining the underlying cause ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...